FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
UroGen Pharma Ltd. URGN — 8-K: Results of Operations and Financial Condition
neutral
UroGen Pharma reported strong Q3 results with $68.0 million in ZUSDURI revenue, representing 35% quarter-over-quarter growth, and announced the FDA's acceptance of the UGN-103 NDA for review, but no significant surprises were disclosed beyond routine quarterly updates and previously announced developments.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →